Skip to main content

Table 4 MOS-Sleep Scale scores at baseline and final assessment

From: A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia

Assessment Baseline mean score ± SD Final assessment LS mean score ± SE Placebo-adjusted LS mean change from baseline with pregabalina
  Placebo Pregabalin Placebo Pregabalin Change 95% CI P-value
Sleep disturbanceb 47.7 ± 26.1 48.0 ± 26.5 39.76 ± 1.31 30.27 ± 1.31 -9.48 -13.12, -5.85 <0.0001*
Sleep adequacy 29.0 ± 23.7 28.7 ± 24.5 36.91 ± 1.41 44.39 ± 1.40 7.48 3.58, 11.38 <0.0001*
Quantity of sleep 5.4 ± 1.4 5.6 ± 1.3 5.70 ± 0.06 5.99 ± 0.06 0.29 0.11, 0.47 0.0007*
Awakening short of breath/headache 25.8 ± 26.6 26.2 ± 26.1 22.99 ± 1.36 18.00 ± 1.36 -4.99 -8.77, -1.21 0.0049*
Snoring 26.5 ± 28.7 25.0 ± 28.1 24.19 ± 1.33 29.17 ± 1.33 4.98 1.29, 8.68 0.9958
Somnolence 41.6 ± 23.3 40.5 ± 24.3 36.41 ± 1.29 47.71 ± 1.28 11.31 7.74, 14.87 1.0000
Overall sleep problems index 49.8 ± 17.2 49.7 ± 18.5 42.66 ± 0.96 39.67 ± 0.95 -2.99 -5.65, -0.33 0.0137*
  1. aDifference in mean change from baseline, compared with placebo using the baseline score as covariate. bMOS-Sleep Scale subscales scored from 0 to 100 with higher scores indicating more of the attribute named in the subscale except for 'quantity of sleep', scored from 0 to 24 indicating the number of hours of sleep.
  2. *Indicates statistical significance at the P <0.025 level.
  3. CI, confidence interval; LS, least squares; MOS, Medical Outcomes Study; SD, standard deviation; SE, standard error